Procedures
EVENTS, DISEASE, SYNDROME, POSITIVE
Participants were screened online and via telephone. Potentially eligible participants attended an in‐person (pre‐coronavirus disease [COVID]) or virtual (post‐COVID) baseline session. In‐person eligibility criteria were confirmed at either the in‐person baseline or first drug administration session.Eligible participants then completed three drug administration sessions. At the start of each session, recent alcohol and illicit drug use were checked to ensure abstinence via an alcohol breathalyser, a saliva drugs test and self‐report. Female participants completed a urine pregnancy test. Drug administration sessions lasted 5–6 h in total. Participants completed assessments before and after cannabis inhalation (Table Schedule of experiment events for drug administration sessions to the nearest 5 min, relative to the start of drug administration (T‐inh)
Abbreviations: BMI = body mass index; BP = blood pressure; HR = heart rate; MRI = magnetic resonance imaging; PANSS = Positive and Negative Syndrome Scale; PSI = Psychotomimetic States Inventory; T‐inh = the time that drug inhalation started; TLFB = timeline follow‐back; VAS = visual analogue scale.Dried medical cannabis flower was procured from Bedrocan (